Azenta Announces the Election of Dipal Doshi to its Board of Directors

Core Insights - Azenta, Inc. has elected Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors during the Annual Meeting of Stockholders [1] - Mr. Doshi is recognized for his significant experience in the biotechnology and pharmaceutical industries, making him a valuable addition to the Board [2] - Mr. Doshi expressed enthusiasm about joining Azenta, highlighting the company's strong market leadership and commitment to growth and innovation [3] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, facilitating faster market access for breakthroughs and therapies [5] - The company offers a comprehensive suite of cold-chain sample management solutions and multiomics services, catering to drug development, clinical research, and advanced cell therapies [5] - Azenta operates globally with a presence in North America, Europe, and Asia, and is headquartered in Burlington, MA [6] Leadership Background - Dipal Doshi has extensive experience in the biotechnology and pharmaceutical sectors, having held critical roles in business development, corporate strategy, and finance [3] - Prior to his role at Entrada Therapeutics, Mr. Doshi served as Chief Business Officer at Amicus Therapeutics and has experience in investment banking with Merrill Lynch [4] - He holds an MBA from The Wharton School and a BA from Rutgers University, and is involved with other organizations in the life sciences sector [4]